论文部分内容阅读
近年来 ,自体骨髓移植 (ABMT)治疗恶性淋巴瘤已取得了长足的进展 ,将可能成为根治恶性淋巴瘤的一线方案。ABMT后存在着复发可能 ,是影响疗效的关键因素。究其原因 ,是体内残留的恶性细胞 ,即微小残留病 (MRD)所致。对MRD的检测和研究是解决恶性淋巴瘤复发的重要手段和途径。我
In recent years, autologous bone marrow transplantation (ABMT) has made great progress in the treatment of malignant lymphoma and may become the first-line regimen for the treatment of malignant lymphoma. ABMT there is the possibility of recurrence, is the key factor affecting the efficacy. The reason is the body of residual malignant cells, minimal residual disease (MRD) due. The detection and research of MRD is an important means and way to solve the recurrence of malignant lymphoma. I